semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C Liver Disease Written informed consent must be obtained before any assessment is performed 2. Participants with HCV genotype 2 or 3 infection who have previously failed interferon therapy or are intolerant or unable to take interferon 3. Males or females aged ≥18 years 4. Diagnosed Chronic hepatitis C virus infection  Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of that medication before enrollment 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 3. Hepatitis B surface antigen (HBsAg) positive 4. Human immunodeficiency virus (HIV) positive Other protocol-defined inclusion/ apply
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C Subjects chronically infected with HCV genotype 1a HCV RNA ≥ 10,000 IU/mL at screening Treatment-naïve subjects with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), ribavirin (RBV), or HCV direct acting antiviral (DAA; protease, polymerase inhibitor, etc.)  Evidence of cirrhosis Liver or any other organ transplant Current or known history of cancer within 5 years prior to enrollment Documented or suspected hepatocellular carcinoma (HCC) Not eligible for sofosbuvir + pegylated interferon + ribavirin therapy
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Chronic Hepatitis C Common with National Program for Viral Hepatitis Age: 18 years to 60 years Positive HCV antibodies using a third generation test Detectable HCV RNA by PCR Liver biopsy showing chronic hepatitis with either a score F1 with elevated liver enzymes or scores F2/F3 Naïve to treatment with PEG-IFN and RBV HBs antigen negative Prothrombin time ≥60 %, normal bilirubin, alpha-foeto protein < 3*normal range of the laboratory, anti-nuclear antibodies<1/160 Effective contraception during the treatment period; no breast-feeding Specific to the trial Prior approval from the Ministry of Health to be treated as part of the National Program with allocation to Peg-IFN α2b treatment Living <100 km from Cairo and able to come to the centre every week for the treatment  Common with National program for Viral Hepatitis Serious co-morbid conditions such as severe hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes (HbA1C>8%) , chronic obstructive pulmonary disease Major uncontrolled depressive illness Solid transplant organ (renal, heart, or lung) Untreated thyroid disease History of previous anti-HCV therapy Body mass index (BMI) greater than 30 kg/m² Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not be proposed or done, patients with known HIV coinfection will not be included in the trial Anti-HCV therapy contraindications hypersensitivity to one of the two drugs (PEG-IFN, RBV)
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Chronic Hepatitis C Age < 18 years and > 60 years Positive HCV antibodies using a third generation test Detectable HCV RNA by PCR Liver biopsy showing chronic hepatitis with either a score F1 with elevated liver enzymes or scores F2/F3 Naïve to treatment with PEG-IFN and RBV HBs antigen negative Prothrombin time ≥60 %, normal bilirubin, alpha-foeto protein < 3*normal range of the laboratory, anti-nuclear antibodies<1/160 Effective contraception during the treatment period; no breast-feeding Signed informed consent and willingness to participate in the study  Serious co-morbid conditions such as severe hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes (HbA1C>8%) , chronic obstructive pulmonary disease Major uncontrolled depressive illness Solid transplant organ (renal, heart, or lung) Untreated thyroid disease History of previous anti-HCV therapy Body mass index (BMI) greater than 30 kg/m² Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not be proposed or done, patients with known HIV coinfection will not be included in the trial hypersensitivity to one of the two drugs (PEG-IFN, RBV) pregnancy or unwilling to comply with adequate contraception breast-feeding
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acquired Immunodeficiency Syndrome Virus Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted Hepatocellular Carcinoma Human immunodeficiency virus chronic infection Hepatitis C virus chronic infection No other liver viral coinfections  Alcohol consume Immunosuppressor or immunoactive treatment
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Chronic hepatitis C defined as detectable HCV RNA for more than 6 months Age > 18 years old Compensated liver disease (bilirubin < 3mg/dL, unless having Gilbert´s syndrome, albumin > 3 g/dL, INR < 2, no hepatic encephalopathy, no ascites or recent -1 month- history of variceal bleeding) HCV RNA level > 10.000 IU/mL Signed informed consent document  History of cholecystectomy or known gallstones Current HCV antiviral treatment Medications for dyslipidemia in the preceding 2 months Abdominal surgery that could alter biliary or intestinal anatomy Evidence of sitosterolemia Negative pregnancy test in urine (for females)
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C Provision of written informed consent Male and female patients aged 18 years and above Willing to use two effective methods of contraception during the treatment period and 24 weeks post HBsAg negative Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the investigator is unlikely to demonstrate spontaneous viral clearance Compensated liver disease (Child-Pugh A) Negative pregnancy test at screening and 24 hours prior to first dose of study drugs Medically stable on the basis of physical examination, medical history and vital signs Adequate English to provide reliable responses to the study questionnaires Recent hepatitis C infection, as defined by: A) i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii) Documented anti-HCV Ab negative within the 24 months prior to anti-HCV antibody positive result, OR B) i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii) acute clinical hepatitis (jaundice or ALT> 10 X ULN) within the previous 12 months prior to first positive HCV antibody or HCV RNA, with no other cause of acute hepatitis identifiable If co-infection with HIV is documented, the subject must meet the following  Standard exclusions to RBV therapy Pregnancy/lactation or male subjects whose female partners are pregnant Subject has a history of decompensated liver disease: history of ascites, hepatic encephalopathy, or bleeding oesophageal varices, and/or any of the following screening laboratory results: a.INR of ≥1.5; Serum albumin <3.3 g/dL; Serum total bilirubin >1.8 times upper limit of normal, unless isolated in subjects with Gilbert's syndrome
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Late Complication From Liver Transplant Adult 20 years and older 2. Chronic infection with genotype 1 hepatitis C virus proven with positive PCR 3. Liver cirrhosis while awaiting liver transplantation 4. Patient with compensated liver functions 5. With or without hepatocellular carcinoma. 6. Naive or experienced (failure) to HCV antiviral treatmentFailure is defined according to the following terminology Relapsing patient: HCV RNA undetectable at the end of treatment, becoming detectable again after the discontinuation of treatment Breakthrough: increase of viremia of 1 log or more during the treatment Non-responding patient with partial response: HCV RNA detectable at W24 without ever having been undetectable and with a decrease in HCV RNA ≥ 2 log at W12 Non-responding patient with null response: decrease in HCV RNA < 2 log at W12 7. No need for prior treatment wash-out 8. Written patient informed consent  Non controlled sepsis 2. Platelets < 50,000/mm3 3. Neutrophil granulocyte levels < 1000/mm3 4. Creatinine clearance < 50 mL/min 5. Hb < 10 g/dL 6. Uncontrolled psychiatric problems 7. Hypersensitivity or contraindications to any component of boceprevir formulation 8. Contraindication to interferon or ribavirin 9. HIV coinfection 10. HBV coinfection (unless this is treated effectively with analogues, as proven by undetectable viremia for at least 12 months) 11. Other infectious disease underway 12. Neoplastic disease other than hepatocellular carcinoma during the previous year, or neoplastic disease for which the prognosis is less than 3 years 13. Treatment with immunosuppressors (including corticosteroids), antivirals other than those for the study, except aciclovir 14. Current or anticipated use of any of the following prohibited medications: midazolam, pimozide, amiodarone, flecainide, propafenone, quinidine, and ergot derivatives 15. Person participating in another study including an period that is still underway during pre-enrollment 16. Pregnancy, breast-feeding
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hepatitis C Virus For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subject chronically infected with HCV genotype 1 (GT-1) Subject without cirrhosis or with compensated cirrhosis (Child Pugh Class A) HCV RNA ≥ 10,000 IU/mL at screening Treatment-naïve subject with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), Ribavirin (RBV), or HCV DAA (protease, polymerase inhibitor, etc.) Interferon (IFN) experienced subject who have received previous treatment with IFNα, with or without RBV  Liver or any other transplant (including hematopoietic stem cell transplants) other than cornea and hair Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening Documented or suspected hepatocellular carcinoma (HCC), as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed) Evidence of decompensated liver disease including, but not limited to, radiologic a history or presence of ascites, bleeding varices, or hepatic encephalopathy
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hepatitis C For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Males and Females ≥18 years of age, inclusive Chronic HCV infection Genotype 1 only Non-cirrhotic Treatment naive subjects with no previous exposure to an Interferon formulation (ie, IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease, polymerase inhibitor, etc.)  HCV Genotype other than Genotype 1 Documented or suspected hepatocellular carcinoma Evidence of decompensated liver disease Contraindication(s) to Peg/RBV therapy
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Liver Disease (CLD) Healthy Volunteers Over 18 years of age 2. Ability and willingness to sign the Informed Consent Form For patient group: 3. a. Known chronic liver disease (based on medical history) For healthy volunteers: 3.b. No known liver disease (based on medical history)  Gastric bypass surgery or extensive small bowel resection 2. Total parenteral nutrition 3. Pregnant or breast feeding 4. Allergy to acetaminophen and/or other related medications. 5. Documented drug-related concurrent hepatotoxicity or drug-related silent steatosis or drug-related fibrosis (e.g. amiodarone, methotrexate and tamoxifen). 6. Uncontrolled malabsorption or diarrhea 7. Placement of a transjugular intrahepatic portosystemic shunt (TIPS) 8. Subject should not have taken any of the following for at least 48 hours prior to the breath test: Acyclovir, allopurinol, carbamazepine, cimetidine, ciprofloxacin, daidzein, (herbal) disulfiram, echinacea, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or oral contraceptives or any medication that might interfere with Methacetin metabolism or might affect CYP 1A2 9. Subject should not have taken amiodarone within the last 30 days prior to the breath test